Nanoparticles for the targeted treatment of infected cells

The National Cancer Institute seeks parties interested in collaborative research to license or co-develop and commercialize therapeutic RNA/DNA nanoparticles.IC: NCINIH Ref. No.: E-039-2012Advantages: Novel way for multiple functionality delivery and activationEnhanced chemical stability and pharmacokinetics due to the average size of nanoparticles exceeding 10nmIncreased specificity for selecting cells of interest   using more than one target geneApplications: Therapeutic siRNA for cancer and viral infections  Diagnostic to visualize cancerous or virus-infected cells or track delivery and effectiveness of siRNA treatment.Research tool to study cancer, viral infection, or other diseasesDevelopment Status: Pre-clinical (in vivo)Updated On: Dec 20, 2017Provider Classifications: Publications: Patent Application: 61/561,257PCT/US2012/06594Patent Number: 9,631,1926,093,7752,780,455Licensing Contacts: Lead Inventor: Inventor IC: NCIInventor Lab URL: https://ccr.cancer.gov/Gene-Regulation-and-Chromosome-Biology-Laboratory/bruce-a-shapiroInv Is lead: LPM Phone: 240-276-5515LPM Email: John.Hewes@nih.govDTDT Classification: TherapeuticsDTDT Description: TherapeuticsPat Filing Date: 2011-11-17T00:00:002012-11-19T00:00:00Patent Issue Date: 2017-04-25T00:00:002017-02-05T00:00:002017-07-05T00:00:00Publication Link: http://www.ncbi.nlm.nih.gov/pubmed/23016824http://www.ncbi.nlm.ni...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research